Japan's Functional Food Labeling Standards After the Kobayashi Recall: What the 2025–2026 Reform Changes

Jun 11, 2026

Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, exercise, or supplement regimen.

In March 2024, Kobayashi Pharmaceutical’s voluntary recall of its beni-koji dietary supplement line became the most concentrated stress test Japan’s functional food regulatory architecture had faced since the 機能性表示食品 (Functional Food Claims, or FFC) notification system launched in 2015. Several of the recalled products had been registered under the FFC system with cholesterol-related claims. The registration process, as structured at that point, had not required the comprehensive secondary metabolite safety documentation that might have flagged the unknown compound or compounds implicated in reported adverse events. The subsequent regulatory review produced changes to how FFC notifications must be substantiated, what post-market obligations fall to manufacturers, and how the Consumer Affairs Agency’s oversight role is positioned relative to the system’s notification-based structure.

This article covers the labeling framework changes specifically. The mechanics of how FOSHU and FFC work are addressed in the FFC and FOSHU system overview. The compound-level evidence and safety science behind the Kobayashi products are covered in detail in Beni-koji and the 2024 recall. The angle here is different: what the reform indicates about the labeling standards themselves, and what overseas buyers reading Japanese functional food labels should understand has changed.

What the investigation revealed about the FFC notification structure

The FFC system operates on a manufacturer-notification model. A company assembles a dossier — either a systematic review of published literature or a manufacturer-conducted trial specific to the product — submits it to the Consumer Affairs Agency’s public database (届出DB), and may begin selling under claim language if the agency raises no objection within a 60-business-day review window. The burden of substantiation sits with the manufacturer; the agency’s role is review and objection, not active pre-market approval.

The safety documentation framework under the pre-reform structure required that manufacturers demonstrate the ingredient’s safety at the claimed dose through literature review or clinical data. What it did not require, at a systematic level, was comprehensive profiling of the secondary metabolite output specific to the manufacturer’s production process — a documentation layer that pharmaceutical GMP frameworks impose but that Japan’s food-tier notification pathway had not applied to the FFC system.

The investigation findings sharpened this gap: Kobayashi’s recalled products reportedly tested below detection limits for citrinin, the known nephrotoxic Monascus secondary metabolite and the compound that standard red yeast rice safety framing addresses. The implication was that standard testing of the known safety-relevant compound was insufficient to characterize what the specific production process had generated. The FFC registration for those products had been supported by a valid evidence submission under the existing framework — and that framework had not caught the problem. The reform question was what minimum documentation a notification system can require for fermentation-derived ingredients while remaining accessible enough to serve its market function.

The reform direction: what the Consumer Affairs Agency outlined

Following the investigation period, the Consumer Affairs Agency’s review process outlined revisions to the FFC notification framework across three areas. These emerged from a study panel process during 2024–2025; the timeline of final implementation is phased and ongoing as of mid-2026.

Safety documentation for fermentation-derived ingredients. The revised guidance extends the safety substantiation requirement for FFC notifications involving fermentation-derived ingredients beyond the ingredient’s known active compound and known risk metabolites. Manufacturers are expected to characterize the manufacturing-process-specific secondary metabolite profile of their specific production approach — not simply the ingredient category’s general safety literature. This is a meaningful shift in documentation scope for fermentation-derived submissions, with no direct pre-reform equivalent in the FFC framework.

Post-market adverse event obligations. The reform direction requires manufacturers to establish structured adverse event surveillance mechanisms and to report significant adverse event patterns to the Consumer Affairs Agency within defined windows. Pre-reform FFC registration was heavily front-loaded: thorough submission documentation, followed by lighter post-market obligations relative to pharmaceutical product tracking. The revised obligations pull the system toward more continuous monitoring, remaining structurally distinct from pharmaceutical pharmacovigilance but closer to it than the prior framework was.

Consumer-facing disclosure language. The mandatory FFC label disclosure — which already states that the Consumer Affairs Agency has not approved the claim and that the product is not a medicine — was supplemented with clearer guidance directing consumers to report adverse reactions directly to the agency. The early phase of the Kobayashi incident was marked by information lag: adverse event reports reached the manufacturer before reaching public health authorities at scale. The revised disclosure language is intended to close part of that reporting gap by making the direct reporting channel visible at the point of product use.

What these changes do not do is convert the FFC system into a pre-authorization regime. Products continue to proceed under a notification model: manufacturers submit, the agency reviews and objects or does not, and products reach market without active approval being granted. The reform raised the documentation floor and strengthened the post-market feedback loop, but the basic architecture remains notification-based.

FOSHU’s individual review model in the post-reform context

Japan’s other functional food tier — FOSHU (特定保健用食品, or Food for Specified Health Uses) — operates under individual product approval from the Ministry of Health, Labour and Welfare. MHLW reviews product-specific clinical trial data submitted by manufacturers before any health claim may appear on the label. The review process typically requires two to five years of clinical documentation, and the resulting approximately 1,000 approved FOSHU products are concentrated among large manufacturers with clinical trial infrastructure.

None of the recalled Kobayashi products were registered under FOSHU; they were FFC notifications. The incident therefore did not create direct pressure on FOSHU’s approval framework in the same way it did on FFC. What it did produce was a renewed policy discussion about what the two-tier structure implies.

The FOSHU individual review model’s resource intensity — which was explicitly why the FFC system was created as a lower-cost pathway in 2015 — is also a safety documentation feature. MHLW’s product-specific review would in principle have required manufacturing process documentation closer to pharmaceutical standards than the FFC notification pathway did. Whether a FOSHU review would have detected the Kobayashi manufacturing process issue is an open question, not a settled one. What the reform trajectory reflects is the Consumer Affairs Agency’s judgment that the FFC pathway’s documentation threshold needed adjustment rather than wholesale replacement with an approval model, on the grounds that the notification structure’s accessibility serves a legitimate market function that converting it to an approval system would eliminate.

How the reformed framework compares to EU Qualified Health Claims and FDA structure/function claims

The Kobayashi-prompted review creates a useful moment to position Japan’s revised system against the other major regulatory frameworks that overseas buyers encounter.

EU Qualified Health Claims: Under EU Regulation 1924/2006, health and nutrition claims on food products in EU member states must receive authorization before use. EFSA evaluates submitted scientific dossiers and issues scientific opinions; the European Commission maintains the authorized claims register. No claim may appear on a product label until it has received a positive EFSA opinion and Commission authorization, or falls under permitted transitional national claims. This pre-authorization design means that safety substantiation — including manufacturing process characterization for novel ingredients — is a precondition, not a post-market obligation. The practical consequence is a narrower authorized claims register than Japan’s FFC notification database, representing a higher evidentiary threshold, with particular stringency for fermentation-derived or novel botanical ingredient categories. EFSA’s 2012 scientific opinion establishing citrinin tolerability limits and its 2018 assessment of monacolin K adverse effect thresholds in red yeast rice supplements illustrate the ingredient-specific depth of that pre-authorization review.

FDA structure/function claims: Under DSHEA (1994), US dietary supplement manufacturers may make structure/function claims — statements that a supplement affects body structure or function — without pre-market authorization. Manufacturers must notify the FDA within 30 days of first marketing a product with such a claim and must be able to substantiate it. The mandatory label disclaimer states that the claim has not been evaluated by the FDA and the product is not intended to diagnose, treat, cure, or prevent any disease. The FDA’s role is post-market: reviewing claims after marketing and taking enforcement action for unsubstantiated disease claims or violations of other provisions. NHANES (National Health and Nutrition Examination Survey) dietary intake data informs FDA assessments of population-level supplement exposure and appears in agency risk assessments for ingredient categories, but it does not function as a claim pre-authorization mechanism; it is a monitoring and surveillance tool rather than a regulatory gate on the notification pathway. The US framework imposes no pre-market safety dossier requirement equivalent to either FOSHU approval or the revised FFC documentation threshold, and post-market adverse event monitoring obligations for supplement manufacturers under current DSHEA implementation are lighter than the Consumer Affairs Agency’s revised FFC requirements.

Japan’s reformed FFC system occupies a middle position. It is closer to the EU in its enhanced safety documentation requirements and strengthened post-market surveillance expectations. It is closer to the US model in its notification-rather-than-authorization structure. The reform moved the system along the spectrum without reaching either pole — a policy calibration that reflects the Consumer Affairs Agency’s objective of maintaining the FFC pathway’s accessibility while addressing the specific manufacturing-process documentation gap the Kobayashi incident exposed.

Reading Japanese functional food labels after the reform

For overseas buyers, the practical implications of the revised framework come down to a few concrete reading differences.

FFC-notified products registered after the 2025 documentation requirements took effect will have met the enhanced safety substantiation floor — including, for fermentation-derived ingredients, the secondary metabolite profiling layer. Products registered before the reform remain in the notification database; the Consumer Affairs Agency’s review of legacy notifications is ongoing and phased rather than requiring immediate re-registration. For fermentation-derived FFC products specifically — beni-koji was the central case, but the revised requirement extends to other fermented botanical categories — checking the notification date in the Consumer Affairs Agency’s publicly searchable 届出DB is a concrete due-diligence step. Post-reform submissions can be assumed to reflect the updated documentation standard; pre-reform submissions carry the lighter prior-framework standard.

FOSHU-approved products were not directly subject to the FFC reform. MHLW’s individual approval process was not materially restructured, though MHLW has signaled closer operational coordination with the Consumer Affairs Agency on manufacturing quality standards for health food products broadly. The FOSHU registry’s approximately 1,000 products continue to represent MHLW-reviewed, formulation-specific clinical evidence for each approved claim.

For ingredient categories with well-established FFC notification records — EPA/DHA omega-3 fatty acids for blood triglyceride claims, specific lactobacillus strains for intestinal regulation claims, lutein for visual function indicators — the reform’s immediate documentation impact is most visible in requirements for newly notified fermentation-derived products in those categories. The Japan supplement regulation update covers where NMN, NR, and related compounds sit relative to both the food regulatory framework and international claim status.

For anyone wanting to understand the academic and policy context behind Japan’s health food labeling approach, English-language resources on the topic are available. Japanese food labeling and safety regulation books on Amazon covers academic and professional texts on the regulatory framework. Functional food health claims science and regulation books on Amazon covers comparative international regulatory coverage including EU and US frameworks alongside Japan’s approach.

Anyone purchasing fermentation-derived Japanese functional food supplements — particularly post-recall beni-koji products or other Monascus-derived categories — should consult a qualified healthcare professional before use. The reformed labeling framework indicates what documentation a manufacturer has submitted; it does not substitute for individual health assessment.